Antisense oligonucleotides

Show results for

Unknown (1870)
Transcriptomics (499)
Genomics (375)
Proteomics (40)
Other (31)
Metabolomics (2)
Models (1)

Organisms

Homo sapiens (252)
Mus musculus (154)
Bos taurus (23)
Danio rerio (18)
Xenopus laevis (12)
Schizosaccharomyces pombe (8)
Sus scrofa (8)
Bordetella bronchiseptica (7)
Rattus norvegicus (7)
Arabidopsis thaliana (6)
Bordetella pertussis (5)
Saccharomyces cerevisiae (5)
Meleagris gallopavo (3)
Fundulus heteroclitus (3)
Oncorhynchus mykiss (3)
Streptococcus uberis (2)
Shewanella oneidensis MR-1 (2)
Bordetella parapertussis (2)
Oryza sativa (2)
Salmo salar (2)
Caenorhabditis elegans (2)
Plasmodium falciparum (2)
Escherichia coli str. K-12 substr. MG1655 (2)
Rattus (1)
Shewanella loihica PV-4 (1)
Shewanella sp. MR-4 (1)
Shewanella sp. ANA-3 (1)
Shewanella sp. MR-7 (1)
Shewanella putrefaciens CN-32 (1)
Shewanella amazonensis SB2B (1)

Organisms

Homo sapiens (160)
Mus musculus (88)
Xenopus laevis (8)
Danio rerio (5)
Rattus norvegicus (3)
Desulfitobacterium hafniense Y51 (2)
Mycobacterium leprae (2)
Xenopus tropicalis (2)
synthetic construct (2)
Patiria miniata (1)
Middle East respiratory syndrome-related coronavirus (1)
Ciona robusta (1)
Mus (1)
Salmo salar (1)
Aedes aegypti (1)
Sus scrofa (1)
Zea mays (1)

Repository

ENA (339)
biostudies-arrayexpress (316)
geo (250)
pride (36)
iProX (2)
MassIVE (2)
MetaboLights (2)
BioModels (1)

Tissue

Cell culture (18)
Permanent cell line cell (5)
Epithelial cell (3)
Fibroblast (3)
Hepatocyte (2)
Liver (2)
Seedling (2)
Blood platelet (1)
Brain (1)
Cervical cancer cell line (1)
Early embryonic cell (1)
Embryonic kidney cell line (1)
Epithelial cell of cervix (1)
Fascia (1)
HiPSC cell (1)
Islet of Langerhans (1)
Lung (1)
Macrophage (1)
Monocyte (1)
Myoblast (1)
Neuron (1)
Pancreatic islet (1)
Plant cell (1)
Plasma cell (1)
Skin (1)

Disease

Colon cancer (5)
Normal (4)
Breast cancer (2)
MAS (1)
Xenografts with H1299 cell line (1)
Triple negative breast cancer (1)
Colon carcinoma (1)
Acute myocardial infarction (1)
Carcinoma (1)
Breast carcinoma (1)
Brain glioblastoma multiforme (1)
Cervix carcinoma (1)
Hepatocellular carcinoma (1)
Huntington Disease (1)
Influenza (1)
Mitochondrial complex I deficiency (1)
Multiple myeloma (1)
Multiple sclerosis (1)
Non-small cell lung carcinoma (1)
Plasmodium falciparum malaria (1)
Retinitis pigmentosa (1)

Technology Type

Mass Spectrometry (36)
Affinity purification coupled with mass spectrometry proteomics (13)
Shotgun proteomics (12)
Bottom-up proteomics (9)
Data-independent acquisition (4)
Data-dependent acquisition (3)
DiaPASEF (3)
Top-down proteomics (2)
NMR spectroscopy (1)
Mass spectrometry (1)
Mass spectrometry assay (1)
All-ion fragmentation (1)
Gel-based experiment (1)
RNA mass spectrometry (1)
SWATH MS (1)

Instrument Platform

NextSeq 500 (12)
Scanning hardware (10)
Illumina HiSeq 2000 (6)
Illumina HiSeq 2500 (5)
Illumina NovaSeq 6000 (5)
Illumina HiSeq 4000 (3)
2100 Bioanalyzer (2)
Illumina NovaSeq X (2)
NextSeq 550 (2)
Tapestation (1)
Bioanalyzer (1)
Covaris S220, Covaris LE220 (1)
PacBio RS II (1)
Applied Biosystems 1700 Chemiluminescent Microarray Analyzer (1)
BD FACSAria III cell sorter (1)
ScanArray 5000 [PerkinElmer] (1)
Illumina Genome Analyzer IIx (1)
ScanArray Express HT [PerkinElmer] (1)
Illumina Genome Analyzer II (1)
Illumina MiSeq (1)
Orbitrap Exploris 480 (1)
Xevo G2-S QTof (1)
Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2026 (78)
2025 (53)
2013 (42)
2012 (41)
2011 (41)
2016 (35)
2015 (34)
2010 (33)
2014 (32)
2023 (30)
2022 (30)
2024 (27)
2021 (20)
2008 (18)
2019 (17)
2009 (17)
2006 (15)
2017 (12)
2018 (9)
2007 (9)
2005 (6)
2020 (6)
2004 (3)
2003 (1)

CHEBI ID

CHEBI:15422 (1)

Metabolite Name

Pc(o-8:0/8:0) (1)
Dgdg(o-10:0/6:0) (1)
3-hydroxy-3-methoxycarbonylpentanedioic acid (1)
Alpha-1,5-L-Arabinobiose (1)
Kaempferol 7-arabinoside (1)
Pseudoecgonyl-CoA (1)
Ancistroquinone B (1)
Nepenthone A (1)
Glochidionolactone A (1)
Leu-Glu-Ser (1)
4''-O-Acetylmyricitrin (1)
Thiophene-2-carboxylic acid (1)
Syringetin-3-o-hexoside (1)
Isorhamnetin 3-rutinoside-7-glucoside (1)
L-fucose 1-phosphate (1)
Kaempferol 3-O-(6''-acetyl-galactoside) 7-O-rhamnoside (1)
Chrysoeriol 7-[feruloyl-(->2)-glucuronyl-(1->2)-glucuronide] (1)
Betanidin 5-[E-feruloyl-(->5)-apiosyl-(1->2)-glucoside] (1)
4-o-beta-d-glucosyl-4-coumaric acid (1)
Epigallocatechin-(4beta->8)-epicatechin 3-O-gallate (1)
Theacitrin C (1)
Assamicain C (1)
1-(4,7-dimethylpyrazolo[5,1-c][1,2,4]triazin-3-yl)ethanone (1)
1,2,3-Tri-O-Galloyl-Beta-D-Glucose (1)
Pi(2:0/2:0) (1)
Calceolarioside E (1)
Beta-D-Glucose 1-phosphate (1)
(-)-Epigallocatechin 3,3'-di-gallate (1)
Epigallocatechin 3-O-gallate-(4beta->6)-epicatechin 3-O-gallate (1)
Purpurogallin-4-carboxylic acid (1)

IsPrivate

False (1)

First Public Date

2026 (73)
2025 (51)
2024 (33)
2022 (27)
2023 (25)
2014 (25)
2021 (22)
2019 (16)
2017 (15)
2018 (12)
2016 (12)
2020 (11)
2015 (11)
2013 (6)

Classification

bacteria (2)
viruses (1)

Modelling Approach

Ordinary differential equation model (1)

Study type

Transcription profiling by array (196)
RNA-seq of coding RNA (47)
Transcription profiling by tiling array (11)
ChIP-seq (11)
RNA-seq of non coding RNA (11)
Other (8)
RNA-seq of total RNA (5)
ChIP-chip by tiling array (4)
RNAi profiling by array (4)
Comparative genomic hybridization by array (3)
ChIP-chip by array (2)
Genotyping by array (2)
MicroRNA profiling by high throughput sequencing (2)
Translation profiling (1)
High-throughput sequencing (1)
Animal - High-throughput sequencing (1)
Cell line - High-throughput sequencing (1)
Transcription profiling by RT-PCR (1)
ATAC-seq (1)
Ribo-seq (1)
MicroRNA profiling by array (1)
Methylation profiling by array (1)
RNA-seq of coding RNA from single cells (1)

Release Date

2023 (189)
2022 (176)
2025 (172)
2021 (169)
2024 (138)
2020 (130)
2018 (114)
2015 (103)
2017 (101)
2014 (101)
2019 (99)
2016 (95)
2013 (94)
2011 (85)
2012 (79)
2010 (60)
2008 (43)
2009 (42)
2006 (33)
2026 (28)
2007 (25)
2004 (25)
2005 (23)
2003 (21)
2002 (13)
2000 (10)
2001 (6)
1999 (4)
1997 (4)
1998 (3)

Lab affiliation

Centre for Cancer Cell & Molecular Biology Barts Cancer Institute Queen Mary University of London Charterhouse Square London EC1M 6BQ U.K. (3)
1)Department of Biomolecular Medicine, Ghent University, Ghent, Belgium 2)Center for Medical Genetics Ghent, Ghent University, Ghent, Belgium 4)Department of Pharmaceutics, Ghent University, Ghent, Belgium (1)
AstraZeneca (1)
Bielefeld University, Faculty of Biology, RNA biology and molecular physiology (1)
Biopharmaceutical development, R&D, AstraZeneca, Cambridge, UK (1)
Cancer Research UK Manchester Institute Transcriptional Networks in Lung Cancer Group (1)
Cancer Science Institute of Singapore (CSI), National University of Singapore (NUS) (1)
Centre for Cancer Cell & Molecular Biology Barts Cancer Institute Queen Mary University of London John Vane Science Centre Charterhouse Square London EC1M 6BQ UK (1)
Cold Spring Harbor Laboratory (1)
Department of Biochemistry & Pharmacology, Bio21 Institute, University of Melbourne (1)
Department of Chemistry, Lomonosov Moscow State University, Leninskye Gory 1, 119991 Moscow, Russia (1)
Department of Chemistry, University of California, Riverside, California, 92521-0403, USA (1)
Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland (1)
Department of Medical Biochemistry and Cell biology, University of Gothenburg (1)
Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany. NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. (1)
German Cancer Research Center (DKFZ) Foundation under Public Law Im Neuenheimer Feld 280 69120 Heidelberg Germany (1)
Head of the Curie Institute Mass Spectrometry Platform (1)
Institute for Cardiovascular Physiology, Faculty of Medicine, Goethe-University; Frankfurt am Main, Germany (1)
Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University Frankfurt am Main, Germany (1)
Institute of Cardiovascular Regeneration Centre of Molecular Medicine, Goethe University, Frankfurt am Main, Germany (1)
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany (1)
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany Gene and RNA Therapy Center (GRTC), Faculty of Medicine, University of Tübingen, Tübingen, Germany (1)
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany Gene and RNA Therapy Center (GRTC), Faculty of Medicine, University of Tübingen, Tübingen, Germany iFIT Cluster of Excellence (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies, University of Tübingen, Tübingen, Germany (1)
King Abdullah University of Science & Technology (KAUST), Biological Environmental Sciences and Engineering Division BESE, KAUST Environmental Epigenetics Program, Thuwal, Saudi Arabia. (1)
Laboratory of RNA Biology Institute of Molecular Genetics of the Czech Academy of Sciences Prague, Czechia (1)
Laboratory of nucleic acids biochemistry, Institute of chemical biology and fundamental medicine SB RAS, Russia (1)
MIRCen, UMR9199, CEA, CNRS, Université Paris-Saclay (1)
MPI of Biochemistry (1)
SQY Therapeutics, 2 Av. de la Source de la Bièvre, 78180 Montigny-le-Bretonneux, France Université de Versailles St- Quentin, U1179 INSERM, UFR des Sciences de la Santé - LIA BAHN CSM, France. (1)
School of Pharmacy and Biomolecular Science, Royal College of Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland (1)

Previous page
1 / 282
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 282
Next page

Sort by:

Relevance

Page size

Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and 6 extracellular vesicles recycling

Next generation modified antisense oligonucleotides (ASOs) are commercially approved new therapeutic modalities, yet poor productive uptake and endosomal entrapment in tumour cells limit their broad application. We compared intracellular traffic of anti KRAS antisense oligonucleotide (AZD4785) in go...

ORGANISM(S): Homo sapiens (Human)

2021-11-10 | PXD027804 | Pride

Antisense oligonucletides Lc-ms/ms

Design and evaluation of universal control antisense oligonucleotides across cellular models

Antisense oligonucleotides (ASOs) are emerging as a promising therapeutic approach for many disorders. Currently, fourteen ASOs have been FDA/EMA-approved, with many more in preclinical development. An important requirement for preclinical studies is the inclusion of negative controls to properly as...

ORGANISM(S): Homo sapiens (Human)

2026-09-01 | PXD070121 | Pride

Antisense oligonucleotides Oligonucleotides

Gene expression profile of modified gapmer antisense oligonucleotides treated mouse liver

PRJNA1225661 | ENA

Transcription profiling of Xenopus laevis early gastrulation embryos injected with antisense oligonucleotides against TBP, TLF or TBP2

Xenopus laevis embryos were injected with antisense oligonucleotides against TBP, TLF or TBP2. Embryos were allowed to develop up to stage 7 (non-injected control embryos) or stage 10.5 (early gastrula, control and antisense injected embryos) and subsequently collected for RNA and protein isolation...

ORGANISM(S): Xenopus laevis

2007-08-29 | E-MEXP-1009 | biostudies-arrayexpress

Targeting Smyd3 by antisense oligonucleotides attenuates liver tumor growth

PRJNA641395 | ENA

Stereo-random Oligonucleotides Enable Efficient Recruitment of ADAR in vitro and in vivo

We used our previously published isASO-ID protocol to identify binders for two different adenosine deaminases acting on RNA- (ADAR-) recruiting antisense oligonucleotides (ONs). The ONs differed in their phosphorothioate content and their RNA editing potency and efficiency through the recruitment of...

ORGANISM(S): Homo sapiens (Human)

2025-07-31 | PXD066763 | Pride

Antisense oligonucleotide Basu Drug protein interactome Rna editing Proximity biotinylation Biotin ligase Silac In situ biotinylation Adar-recruiting oligonucleotides

Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.

Not available

S-EPMC4027159 | biostudies-literature

Silencing of NFYC-AS1 by Gapmer antisense oligonucleotides and CRISPR/Cas9 TSS deletion.

PRJNA1003851 | ENA

Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides.

Not available

S-EPMC5009748 | biostudies-literature

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.

Not available

S-EPMC6731179 | biostudies-literature

Previous page
1 / 282
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 282
Next page

Sort by:

Relevance

Page size

2818 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

IsPrivate

First Public Date

Classification

Modelling Approach

Study type

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets